MAPK/ERK在卵巢上皮性癌标本及细胞中的表达及意义
该研究检测104例卵巢上皮性癌组织中p-ERK1/2蛋白表达并分析其与临床病理特征的关系,同时在9种卵巢癌细胞中观察MEK抑制剂AZD6244对增殖、凋亡及细胞周期的影响;结果显示p-ERK1/2在组织和细胞中均有表达,AZD6244可下调p-ERK1/2并抑制增殖、诱导凋亡。
要点
- 104例卵巢癌组织中p-ERK1/2阳性表达率与年龄、病理类型、手术病理分期、术前血清CA125水平均无明显相关性(P>0.05)。
- 高级别浆液性癌、黏液性癌及子宫内膜样癌的p-ERK1/2阳性表达率均低于低级别浆液性癌(均P<0.05)。
- AZD6244(5、10 μmol/L)可下调OVCAR5和OVCAR8细胞p-ERK1/2并诱导凋亡及G0/G1期阻滞,呈浓度依赖性。
核心结论
- p-ERK1/2蛋白在卵巢癌组织和多种卵巢癌细胞中均有不同程度的表达。
- MEK抑制剂AZD6244可抑制卵巢癌细胞增殖、诱发凋亡。
- 作者认为MAPK/ERK信号通路可能在卵巢癌发生、发展中起一定作用,抑制该通路有望成为临床治疗卵巢癌的新靶点。
研究设计与样本
- 回顾性收集2004年1月至2013年12月大连医科大学附属第一医院收治的术后病理证实为卵巢癌的104例患者石蜡标本,采用免疫组化SP法检测p-ERK1/2蛋白表达并分析其与临床病理特征的关系。
- 体外实验采用蛋白印迹法检测9种卵巢癌细胞(SKOV3、OV2008、C13、A2780S、A2780CP、OVCAR4、OVCAR5、OVCAR8和CAOV3)中p-ERK1/2、ERK1/2蛋白表达,MTT法检测AZD6244作用后细胞增殖,流式细胞仪检测凋亡率及细胞周期比例。
主要发现
- p-ERK1/2蛋白阳性表达率与卵巢癌患者年龄、病理类型、手术病理分期、术前血清CA125水平均无明显相关性(P>0.05)。
- 高级别浆液性癌、黏液性癌及子宫内膜样癌的p-ERK1/2阳性表达率均低于低级别浆液性癌,分别比较差异均有统计学意义(P<0.05);透明细胞癌与低级别浆液性癌比较差异无统计学意义(P=0.196)。
- 蛋白印迹法显示p-ERK1/2、ERK1/2蛋白在9种卵巢癌细胞中均有不同程度表达;AZD6244(5、10 μmol/L)作用于OVCAR5和OVCAR8细胞后可抑制p-ERK1/2、细胞周期蛋白D1、caspase-3、PARP蛋白表达,并伴有PARP裂解片段出现。
- MTT法显示不同浓度(0、2.5、5、10、25、50、100 μmol/L)AZD6244作用后,OVCAR5、OVCAR8和A2780S细胞增殖的抑制率均随AZD6244浓度增高而降低,呈显著浓度依赖性(P<0.05)。
- 流式细胞仪显示不同浓度(0、5、10 μmol/L)AZD6244作用后,OVCAR5、OVCAR8和A2780S细胞凋亡率均随浓度增高而增高,呈显著浓度依赖性(P<0.01);OVCAR5和OVCAR8细胞G0/G1期比例显著增高、S期比例显著降低,呈显著浓度依赖性(P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To detect phosphorylated-extracellular signal-regulated kinase (p-ERK1/2) protein expression in epithelial ovarian cancer and cell lines, and to examine the effects of mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor AZD6244 on cell proliferation, apoptosis as well as cell cycle of ovarian cancer cells. To explore the function and significance of MAPK/extracellular signal-regulated kinase (ERK) signaling pathway in the development of ovarian cancer. Methods: (1) A total of 104 cases of patients with ovarian cancer who accepted the treatment of gynecological surgery and being confirmed by pathological examination in First Affiliated Hospital, Dalian Medical University from January 2004 to December 2013 were selected. The expressions of p-ERK1/2 protein were detected by immunohistochemistry in ovarian cancer specimens, and the relationship between the expressions of p-ERK1/2 and the clinical features of patients was analyzed. (2) p-ERK1/2 and other related proteins were determined by western blot in various ovarian cancer cells, including SKOV3, OV2008, C13, A2780S, A2780CP, OVCAR4, OVCAR5, OVCAR8 and CAOV3 treated with or without MEK inhibitor. The cellular proliferation, apoptosis and cell cycle of ovarian cancer cells after treatment with MEK inhibitor were analyzed by methyl thiazolyl tetrazolium (MTT) assay and flow cytometry, respectively. Results: (1) The immunohistochemical method showed that p-ERK1/2 between low grade serous carcinoma and clear cell carcinoma were not significantly higher expressed (P>0.05) . However, a lower level of the p-ERK1/2 expression were observed among high grade serous carcinoma, mucinous carcinoma and endometrioid carcinoma (all P<0.05) . There was no significant correlation between the protein expression of p-ERK1/2 and patients' age, pathological stage of surgery, and preoperative serum CA(125) level (P>0.05). (2) Western blot showed that the protein p-ERK1/2 was widely expressed in various ovarian cancer cell lines such as SKOV3, OV2008, C13, A2780S, A2780CP, OVCAR4, OVCAR5, OVCAR8 and CAOV3. After treatment with AZD6244 (5, 10 μmol/L), the level of p-ERK1/2 in OVCAR5 and OVCAR8 decreased significantly in dose-dependent manner. Additionally, we found a reduction of the expression level of cyclin D1, caspase-3 and appeared cleaved poly adenosine diphosphate ribose polymerase (PARP) in OVCAR5 and OVCAR8, compared with control groups. MTT assays showed that OVCAR5, OVCAR8 and A2780S were differently inhibited in the dose-dependent manner after being treated with different concentrations of AZD6244 (0, 2.5, 5, 10, 25, 50 and 100 μmol/L, all P<0.05). Further tested by flow cytometry, the results showed that AZD6244 (5, 10 μmol/L) was able to induce the apoptosis of OVCAR5, OVCAR8 and A2780S, as well as G(0)/G(1) phase arrest, both in a dose-dependent manner (P<0.05). Conclusions: As the main active and functional unit of MAPK/ERK signaling pathway, p-ERK1/2 protein is expressed in both the tissues and various ovarian cancer cell lines. AZD6244 could down-regulated the expression of p-ERK1/2 in ovarian cancer cells, accompanied by the decreased proliferation and increased cell apoptosis of ovarian cancer cells. In conclusion, MAPK/ERK signaling pathway might play a role in the development and progression of ovarian cancer, and may be provide a novel option for molecular targeted therapies of the disease. 目的: 探讨有丝分裂原活化蛋白激酶(MAPK)/细胞外信号调节激酶(ERK)信号通路在卵巢上皮性癌(卵巢癌)组织和细胞中的表达及其临床意义。 方法: (1)收集2004年1月—2013年12月大连医科大学附属第一医院收治的术后病理检查证实为卵巢癌的104例患者的石蜡标本,采用免疫组化SP法检测卵巢癌组织中磷酸化ERK1/2(p-ERK1/2)蛋白的表达,并分析其与各临床病理特征的关系。(2)蛋白印迹(western blot)法检测MAPK激酶(MEK)抑制剂——司美替尼(AZD6244)作用前后不同卵巢癌细胞(包括SKOV3、OV2008、C13、A2780S、A2780CP、OVCAR4、OVCAR5、OVCAR8和CAOV3细胞共9种)中p-ERK1/2、ERK1/2蛋白的表达,四甲基偶氮唑蓝(MTT)比色法检测AZD6244作用后不同卵巢癌细胞的增殖情况,流式细胞仪检测AZD6244作用后不同卵巢癌细胞的凋亡率及细胞周期比例。 结果: (1)免疫组化SP法检测显示,p-ERK1/2蛋白的阳性表达率与卵巢癌患者的年龄、病理类型、手术病理分期、术前血清CA(125)水平均无明显相关性(P>0.05)。进一步分析发现,在不同病理类型的卵巢癌组织中,p-ERK1/2蛋白的阳性表达率,高级别浆液性癌、黏液性癌及子宫内膜样癌均低于低级别浆液性癌(LGSC),分别比较,差异均有统计学意义(P<0.05);而透明细胞癌与LGSC比较,差异则无统计学意义(P=0.196)。(2)western blot法检测显示,p-ERK1/2、ERK1/2蛋白在9种卵巢癌细胞中均有不同程度的表达;不同浓度(5、10 μmol/L)的AZD6244分别作用于OVCAR5和OVCAR8细胞后,均可抑制p-ERK1/2、细胞周期蛋白D1(cyclin D1)、半胱氨酸天冬氨酸蛋白酶3(caspase-3)、聚二磷酸腺苷核糖聚合酶(PARP)蛋白的表达,且AZD6244作用后可伴有PARP裂解片段的出现。MTT比色法检测显示,不同浓度(0、2.5、5、10、25、50、100 μmol/L)的AZD6244作用后,OVCAR5、OVCAR8和A2780S细胞增殖的抑制率均随着AZD6244浓度的增高而降低,呈显著的浓度依赖性(P<0.05)。流式细胞仪检测显示,不同浓度(0、5、10 μmol/L)的AZD6244作用后,OVCAR5、OVCAR8和A2780S细胞的凋亡率均随着AZD6244浓度的增高而增高,呈显著的浓度依赖性(P<0.01);OVCAR5和OVCAR8细胞的G(0)/G(1)期比例显著增高,S期比例显著降低,呈显著的浓度依赖性(P<0.05)。 结论: 作为MAPK/ERK信号通路的活化形式和功能单位,p-ERK1/2蛋白在卵巢癌组织和细胞中均有不同程度的表达,MEK抑制剂可抑制卵巢癌细胞的增殖、诱发卵巢癌细胞的凋亡。提示,MAPK/ERK信号通路可能在卵巢癌发生、发展中起一定作用,抑制该信号通路有望成为临床治疗卵巢癌的新靶点。.
引用
- Jiang XL, Gao JC, Jiang L, et al. [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi. 2019. PMID: 31461811. doi:10.3760/cma.j.issn.0529-567x.2019.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。